Folate and vitamin B12 supplementation in patients with schizophrenia and low serum folate level: A 24-week randomized, double-blind, placebo-controlled study

What Was Tested

The paper reports a study of Cyanocobalamin (Vitamin B12), published as a randomized controlled trial.

The researchers aimed to evaluate the effects of folate and vitamin B12 on psychopathology in patients with schizophrenia and low serum folate levels.

Who Took Part

The age groups tagged for this paper are young adults, adults and middle-aged adults, both men and women.

The researchers evaluated patients' symptomatology with the Positive and Negative Symptom Scale (PANSS) and cognitive functions with Cogstate.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Cyanocobalamin (Vitamin B12) group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Cyanocobalamin (Vitamin B12).

The comparison arm used a placebo, so changes seen with Cyanocobalamin (Vitamin B12) could be set against what happens without it.

What Was Measured

The subject headings attached to it are Cognition, Dietary Supplements, Folic Acid, Homocysteine, Psychiatric Status Rating Scales, Schizophrenia and Vitamin B 12.

The authors tagged it with the keywords Cognitive functions, Folate, One-carbon metabolism and Psychopathology.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Cyanocobalamin (Vitamin B12).

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2026 (Journal of the Formosan Medical Association = Taiwan yi zhi), a journal based in Singapore.

More context: the Cyanocobalamin (Vitamin B12) compound page, all human trials.